<DOC>
	<DOCNO>NCT03041909</DOCNO>
	<brief_summary>This open label , single arm study enroll 16 subject SCD previously participate GBT440-001 study . Dosing study drug 2 6 month , depend subject 's dose assignment last administration study drug GBT440-001 . The primary objective study evaluate safety tolerability total 6 month dose subject SCD participate GBT440-001 study .</brief_summary>
	<brief_title>An Extension Study Further Evaluate Safety , Tolerability GBT440 Patients With Sickle Cell Disease Who Participated Study GBT440-001</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>1 . Male female subject SCD age 18 60 year inclusive &gt; 50 kg participate GBT440001 study . 2 . Subjects , female child bear potential , agree continue use highly effective method contraception prior enrollment study 3 month last dose study drug . 3 . Subjects , male willing continue use barrier method contraception , prior enrollment study 3 month last dose study drug . 1 . Subjects require chronic transfusion therapy . 2 . Subjects receive blood transfusion within 30 day enrollment study . 3 . Female subject pregnant , try become pregnant lactating . 4 . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder , additional risk factor torsades de pointe ( e.g. , heart failure , hypokalemia , personal family history long QTc interval ) . 5 . Subjects significant infection know inflammatory process admission study . 6 . Subjects acute gastrointestinal symptom time admission ( e.g . nausea , vomit , diarrhoea , heartburn ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>